吉非替尼治疗对化疗耐药的中晚期非小细胞肺癌62例疗效分析

　　【摘要】目的 观察应用吉非替尼治疗对化疗耐药的中晚期非小细胞肺癌的疗效和不良反应，以及对生活质量的影响。方法 62例既往化疗失败的Ⅲb～Ⅳ期非小细胞肺癌患者，口服吉非替尼250 mg/d，服药至病情进展或出现不能耐受的不良反应，观察吉非替尼的疗效和不良反应，以及患者的生活质量。结果 62例患者均可评价疗效，其中CR 2例，PR 16例，SD 38例，PD 6例，总有效率(RR)为29.0%(18/62)，临床受益率90.3%(56/62)，ECOG评分稳定及改善为71.0%(44/62)。最常见的不良反应为皮疹(27.4%)，多伴发皮肤干燥和瘙痒。结论 吉非替尼对化疗耐药的中晚期非小细胞肺癌疗效确切，改善生活质量且不良反应轻，耐受性好。

　　【关键词】 吉非替尼 非小细胞肺癌 表皮生长因子受体

　　Treated with gifitinib in sixty-two patients with chemotherapy resistant advanced non-small cell lung cancer

　　Chen Dongshen,Yu Xiaofeng

　　Department of Oncology,Zhanjiang Central Hospital of Guangdong Medical College,Zhanjiang 524037,China

　　[Abstract] Objective To investigate the antitumor effect, adverse reactions, and quality of life of gefitinib treatment in treating advanced non-small cell lung cancer. Methods Sixty-two patients with Ⅲb to Ⅳ NSCLC who had previously treated with 2-7 cycles of platinum-based chemotherapy were enrolled into the study. The regimen was oral intake of gefitinib 250 mg once daily until the disease progression or intolerable toxic reaction occurred. The efficacy adverse reactions of gefitinib and quality of life of patients were observed.Results All 62 patients were evaluable for therapeutic effect. Among the 62 patients , 2 cases got complete respose(CR), 16 partial response(PR), 38 stable disease(SD) and 6 progression(PD). The total response rate was 29.0% (18/62)and the disease control rate was 90.3%.(56/62)，and ECOG score was improved or remained stable in 71.0%(44/62). The major adverse reactions of gefitinib included rash, itching and diarrhea. Conclusion Gefitinib was effective and safe for patients with advanced non-small cell lung cancer who failed prior chemotherapy and radiotherapy. The toxicities of gefitinib were tolerable.

　　[Key words] Gefitinib;Non-small cell lung cancer;Epidermal growth factor receptor

　　肺癌是最常见的恶性肿瘤之一，居我国城市恶性肿瘤发病率和病死率首位。非小细胞肺癌(NSCLC)占肺癌的80%～85%，70%～80%的患者发现时已为晚期，5年生存率不足5%。含铂类药物的联合化疗

[1] [2] [3] 下一页